The Type 1 diabetes clinical research team at Indiana University School of Medicine is working to advance detection and treatment for people at all stages of diabetes development and progression.
The three main goals of the research team are to prevent disease development in people who are high risk, preserve beta cell function in newly diagnosed patients, and improve quality of life through technology and therapeutics in persons with established diabetes.
Learn more about the focus and phases of clinical research and explore additional active studies conducted by IU School of Medicine physician investigators.
Currently, the clinical research team is conducting studies involving people who have a high risk for Type 1 diabetes, patients with newly diagnosed Type 1 diabetes and people with established Type 1 diabetes.
Questions or requests for additional information may be directed via email to a study coordinator.
The purpose of this observational study is to develop and validate a novel continuous glucose monitor based index for precise identification of progression across early-stage Type 1 diabetes.
Study coordinator: Riley Pediatric Diabetes Research Team, pedsdiab@iu.edu
The purpose of this observational study is to detect Type 1 diabetes at its earliest stages. Family members of people with Type 1 diabetes are screened for autoantibodies associated with Type 1 diabetes development.
Study coordinator: Alyssa Orlando, alysorla@iu.edu
The purpose of this prospective observational study in prepubertal children recently diagnosed with Type 1 diabetes and similar children without diabetes is to evaluate neurocognitive impact and identify potential clinical, developmental, and/or environmental factors, which may exacerbate or protect against neurocognitive difficulties in Type 1 diabetes.
Study coordinator: Angelica Dillon, atmckibb@iu.edu
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics and efficacy of CNP-103 in patients newly diagnosed with Type 1 diabetes.
The purpose of this study is to develop and validate biomarkers that predict T1D disease risk and document disease progression based on blood and urine indicators of beta cell stress and death in persons with emerging and established T1D.
Study coordinator: Sana Kalaji, skalaji@iu.edu
The purpose of this study is to evaluate the use of inhaled insulin with basal insulin for youth with newly diagnosed Type 1 diabetes.
Study coordinator: Maria Spall, malnicho@iu.edu
The purpose of this study is to evaluate the use of rezpegaldesleukin to preserve insulin production in adults who are newly diagnosed with Type 1 diabetes.
Study coordinator: Maria Spall, malnicho@iu.edu
The purpose of this study is to evaluate the safety and efficacy of SAB-142 for delaying the progression of diabetes in patients newly diagnosed with Type 1 diabetes.
Study coordinator: Hannah Lease, hlease@iu.edu
The purpose of this study is to evaluate the safety and efficacy of Anti-thymocyte globulin (ATG) followed by either adalimumab or verapamil in preserving insulin secretion in patients newly diagnosed with Type 1 diabetes.
Study coordinator: Hannah Lease, hlease@iu.edu
The purpose of this study is to determine the safety and efficacy of denosumab in improving beta cell function and glycemic control among patients with Type 1 diabetes.
With consent from participants the Type 1 diabetes Research Team collects and securely stores information to determine eligibility for future research studies. If a person in the database appears to meet criteria for inclusion in a future study, they can be contacted by the research team to see if they would like additional information about participating.
